or Try an Advanced Search...

    Technical Analysis for GTHX - G1 Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 3.99 3.37% 0.13
    GTHX closed up 3.37 percent on Friday, April 26, 2024, on 45 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 1
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical GTHX trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Strong but Oversold Other 0.00%
    Strong, Oversold and Reversal Signs Reversal 0.00%
    Oversold Stochastic Weakness 0.00%
    Bollinger Band Squeeze Range Contraction 3.37%
    NR7 Range Contraction 3.37%
    Narrow Range Bar Range Contraction 3.37%
    Strong but Oversold Other 3.37%
    BB Squeeze + Lower Band Touch Range Contraction 3.37%
    Older End-of-Day Signals for GTHX ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 18 hours ago
    Rose Above Previous Day's High about 19 hours ago
    Up 2% about 19 hours ago
    Up 1% about 19 hours ago
    Lower Bollinger Band Support 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GTHX Chart by TradingView
    Basic chart:

    Profile

    G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Protein Kinase Inhibitor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant

    Is GTHX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 19 G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
    Apr 17 G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
    Apr 12 Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
    Apr 4 G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Mar 22 Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
    Feb 29 G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
    Feb 29 Q4 2023 G1 Therapeutics Inc Earnings Call
    Feb 28 G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
    Feb 28 G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
    Feb 28 G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023
    See more GTHX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.0
    52 Week Low 1.08
    Average Volume 972,837
    200-Day Moving Average 2.62
    50-Day Moving Average 3.72
    20-Day Moving Average 4.39
    10-Day Moving Average 4.11
    Average True Range 0.31
    RSI (14) 46.24
    ADX 19.71
    +DI 16.92
    -DI 23.44
    Chandelier Exit (Long, 3 ATRs) 3.96
    Chandelier Exit (Short, 3 ATRs) 4.71
    Upper Bollinger Bands 5.01
    Lower Bollinger Band 3.78
    Percent B (%b) 0.17
    BandWidth 27.99
    MACD Line 0.01
    MACD Signal Line 0.12
    MACD Histogram -0.1008
    Fundamentals Value
    Market Cap 206.86 Million
    Num Shares 51.8 Million
    EPS -1.43
    Price-to-Earnings (P/E) Ratio -2.79
    Price-to-Sales 3.08
    Price-to-Book 5.46
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.30
    Resistance 3 (R3) 4.28 4.16 4.25
    Resistance 2 (R2) 4.16 4.09 4.17 4.23
    Resistance 1 (R1) 4.08 4.04 4.12 4.09 4.21
    Pivot Point 3.96 3.96 3.98 3.97 3.96
    Support 1 (S1) 3.87 3.88 3.92 3.89 3.77
    Support 2 (S2) 3.75 3.83 3.76 3.75
    Support 3 (S3) 3.67 3.75 3.73
    Support 4 (S4) 3.68